north cannabis company

North cannabis company

The best cannabis industry news sent to your inbox every Sunday

Join 420 Investor

The largest and most comprehensive premium subscription service for cannabis traders and investors since 2013.



  • Specialty Finance Company Focused on Restructuring Canadian Cannabis Assets
  • Focused on Operating Profitably in Geographically Clustered Markets
  • A Diversified, Multi-State Cannabis Operator with a Focus on Health & Wellness
  • Bringing Leading Branded Cannabis Products to the California Market
  • The Longest Running Cannabis Retailer in California
  • Growing Diverse Cannabis Brands and Stores in Key States
  • A Leading Independent Adult-use Cannabis Retailer
  • An American Leading Science-focused Multi-state Cannabis Operator
  • Artisinal Edibles for High Functioning Adults
  • Focused on owning the branded product space
  • Vertically Integrated Cannabis Holding Company
  • Market share leader in hemp-based CBD wellness products
  • Leaders in Professional Cannabis
  • A Different Kind of Cannabis Company
  • Cannabis Dispensary Marketing Engine
  • Cannabis Industry Compliant Packaging Solutions

Latest News

Ayr Strategies to Begin Trading Immediately on OTC Under New Symbol “AYRWF”

TORONTO, Dec. 04, 2020 (GLOBE NEWSWIRE) — Ayr Strategies.

Curaleaf’s New CEO Talks Plans to Leverage the Company’s Platform to Build National Cannabis Brands

Exclusive Interview with Curaleaf President and Incoming CEO Joseph.

Get The App

Download the free “New Cannabis Ventures” app on the iOS App Store or Google Play and get real-time push notifications straight to your phone on the latest breaking news and exclusives published.

NCV Media

Thank you for reading
New Cannabis Ventures

Contributing original content and curating quality news on only the most promising cannabis companies and the most influential investors.

North cannabis company The best cannabis industry news sent to your inbox every Sunday Join 420 Investor The largest and most comprehensive premium subscription service for cannabis

Top Canadian Cannabis Companies by Revenue

Top Canadian Cannabis Companies by Revenue


Since the legalization of cannabis in Canada in 2018, the past few years have seen a burgeoning growth for Canadian marijuana companies across the nation. As legalization continued to spread—including throughout parts of the bordering U.S.—Canadian cannabis companies and investors alike saw a major opportunity. More and more companies have launched, and some major non-cannabis companies, like beverage producer Constellation Brands (STZ), have invested heavily in cannabis-focused businesses in a show of support for the future of the industry.

For many investors, the proof of a cannabis company’s success is similar to that of any other company’s: it’s in the financials. Now that Canadian cannabis companies have reported their first sets of financial results since legalization took place, analysts can get a better sense of just how justified (or not) the hype has been. Below, we’ll take a look at the top revenue-generating Canadian marijuana companies, per the most recent financial information available.

1. Canopy Growth Corp.

Market cap: $6.76 billion  

Canopy Growth Corp. (CGC) is an Ontario-based company that has the distinction of having been the first federally-regulated and licensed publicly-traded cannabis grower in North America.   Now, thanks in part to an investment of close to $4 billion by Constellation Brands in August of 2018, Canopy Growth is the largest marijuana company in existence as of this writing and per market capitalization.  

Canopy Growth Corp. reported on its final-quarter results from 2019 early in the new year, and the figures boast some impressive accomplishments. The company made a whopping $90.5 million in the first fiscal quarter of 2020 and is positioning itself to bring CBD products to the U.S. market by the end of the fiscal year.   With increased harvests and demand for medical cannabis, Canopy is staying busy: to date, it has a portfolio of 111 patents and 270 applications.  

2. Cronos Group

Market cap: $2.36 billion  

Cronos Group (CRON)’s reach is astounding: the cannabinoid company is already boasting international production and distribution across five continents, building products from hemp-derived CBD for wellness to vape pens.   While there has been some recent volatility in the stock due to a class action filed against Cronos, their shares have also been indicative that cannabis sales and deliveries may rise.  

According to the company, Cronos Group generated $7.64 million (CAD) in revenue in the third fiscal quarter of 2019, which a significant year-over-year increase due to the launch of the adult-use market in Canada.  

3. Aurora Cannabis

Market cap: $1.15 billion  

Headquartered in Edmonton, Aurora Cannabis (ACB) is a major cannabis producer and a licensed distributor.   Aurora boasts a strong international presence, having purchased Berlin-based Pedanios GmbH and having received a supply agreement through a subsidiary called Pedanios to the Italian cannabis market as well.   It also purchased MedReleaf and CanniMed in 2018.  

Aurora’s financials for its 2019 Q4 were quite strong compared with previous quarters as well, generating net revenue of roughly CAD$95 million. In fact, net revenue increased by 61% from the previous quarter.  

4. Aphria

Market cap: $1.37 billion  

Founded in 2014, Aphria (APHA) is a relatively new entrant into the legal cannabis space.   It focuses on medical cannabis, having first received a license to produce and sell medical products. In recent months and in an effort to expand into the U.S. market, Aphria has engaged in high profile (and sometimes highly controversial) acquisitions. For the last fiscal quarter of 2019, Aphria reported net revenue of CAD$128.6 million.  

The Bottom Line

With skyrocketing growth among Canadian cannabis companies, eager investors are riding the wave as legalization spreads around the world. Any investors should also be wary of claims that the cannabis industry more broadly is overblown, with companies potentially extending themselves too far in a bid to buy up competitors, expand growing and production capabilities, and prepare for an industry that enjoys worldwide dominance. Looking ahead, the next test of these businesses will be whether they are able to sustain such impressive revenue growth quarter-over-quarter going into the future.

These companies have been able to provide the top revenue figures in the industry, but whether it's enough to justify investor hype is undetermined.